Pembrolizumab for treatment-related neuroendocrine prostate carcinoma with a high tumor mutational burden: a case report
{{output}}
Pembrolizumab has emerged as a significant therapeutic option for the treatment of solid tumors with a high tumor mutational burden (TMB-high). However, there have been no reports of its use in treatment-related neuroendocrine prostate carcinoma (t-NEPC) with ... ...
